Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide.

Yan SD, Roher A, Chaney M, Zlokovic B, Schmidt AM, Stern D.

Biochim Biophys Acta. 2000 Jul 26;1502(1):145-57. Review.

2.

RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease.

Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD.

Curr Mol Med. 2007 Dec;7(8):735-42. Review.

PMID:
18331231
3.

RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?

Yan SD, Bierhaus A, Nawroth PP, Stern DM.

J Alzheimers Dis. 2009;16(4):833-43. doi: 10.3233/JAD-2009-1030. Review.

4.

Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease.

Du Yan S, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth T, Chen X, Godman GC, Stern D, Schmidt AM.

Proc Natl Acad Sci U S A. 1997 May 13;94(10):5296-301.

5.

Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism.

Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD.

Exp Neurol. 2001 Sep;171(1):29-45.

PMID:
11520119
6.

RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease.

Yan SS, Chen D, Yan S, Guo L, Du H, Chen JX.

Front Biosci (Schol Ed). 2012 Jan 1;4:240-50. Review.

7.

A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease.

Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, Thiyagarajan M, Zarcone T, Fritz G, Friedman AE, Miller BL, Zlokovic BV.

J Clin Invest. 2012 Apr;122(4):1377-92. doi: 10.1172/JCI58642. Epub 2012 Mar 12.

8.

Aβ1-42 reduces P-glycoprotein in the blood-brain barrier through RAGE-NF-κB signaling.

Park R, Kook SY, Park JC, Mook-Jung I.

Cell Death Dis. 2014 Jun 26;5:e1299. doi: 10.1038/cddis.2014.258.

9.

Aβ₁₋₄₂-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca²⁺-calcineurin signaling.

Kook SY, Hong HS, Moon M, Ha CM, Chang S, Mook-Jung I.

J Neurosci. 2012 Jun 27;32(26):8845-54. doi: 10.1523/JNEUROSCI.6102-11.2012.

10.

Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.

Lue LF, Yan SD, Stern DM, Walker DG.

Curr Drug Targets CNS Neurol Disord. 2005 Jun;4(3):249-66. Review.

PMID:
15975028
11.

Ovariectomy increases neuronal amyloid-beta binding alcohol dehydrogenase level in the mouse hippocampus.

Fukuzaki E, Takuma K, Funatsu Y, Himeno Y, Kitahara Y, Gu B, Mizoguchi H, Ibi D, Koike K, Inoue M, Yan SD, Yamada K.

Neurochem Int. 2008 Jun;52(7):1358-64. doi: 10.1016/j.neuint.2008.02.004. Epub 2008 Mar 10.

12.

The interaction of amyloid β and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells.

Du H, Li P, Wang J, Qing X, Li W.

Cell Mol Neurobiol. 2012 Jan;32(1):141-7. doi: 10.1007/s10571-011-9744-8. Epub 2011 Aug 12.

PMID:
21837459
13.

RAGE does not affect amyloid pathology in transgenic ArcAbeta mice.

Vodopivec I, Galichet A, Knobloch M, Bierhaus A, Heizmann CW, Nitsch RM.

Neurodegener Dis. 2009;6(5-6):270-80. doi: 10.1159/000261723. Epub 2010 Feb 10.

PMID:
20145420
14.

A specific RAGE-binding peptide biopanning from phage display random peptide library that ameliorates symptoms in amyloid β peptide-mediated neuronal disorder.

Cai C, Dai X, Zhu Y, Lian M, Xiao F, Dong F, Zhang Q, Huang Y, Zheng Q.

Appl Microbiol Biotechnol. 2016 Jan;100(2):825-35. doi: 10.1007/s00253-015-7001-7. Epub 2015 Oct 24.

PMID:
26496918
15.

Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease.

Jaya Prasanthi RP, Schommer E, Thomasson S, Thompson A, Feist G, Ghribi O.

Mech Ageing Dev. 2008 Nov;129(11):649-55. doi: 10.1016/j.mad.2008.09.002. Epub 2008 Sep 19.

16.

RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model.

Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ, Huh K, Mook-Jung I.

FASEB J. 2009 Aug;23(8):2639-49. doi: 10.1096/fj.08-126383. Epub 2009 Mar 30.

PMID:
19332646
17.

RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling.

Chaney MO, Stine WB, Kokjohn TA, Kuo YM, Esh C, Rahman A, Luehrs DC, Schmidt AM, Stern D, Yan SD, Roher AE.

Biochim Biophys Acta. 2005 Jun 30;1741(1-2):199-205. Epub 2005 Apr 19.

18.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
19.

Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease.

Zhang L, Postina R, Wang Y.

Cell Mol Life Sci. 2009 Dec;66(24):3923-35. doi: 10.1007/s00018-009-0121-4. Review.

PMID:
19672558
20.

Glycation exacerbates the neuronal toxicity of β-amyloid.

Li XH, Du LL, Cheng XS, Jiang X, Zhang Y, Lv BL, Liu R, Wang JZ, Zhou XW.

Cell Death Dis. 2013 Jun 13;4:e673. doi: 10.1038/cddis.2013.180.

Supplemental Content

Support Center